|
May 15
|
CTSO: CytoSorbents Potential for High Margin Revenue Growth Supports Price Target of $4.00
|
|
May 12
|
Cytosorbents First Quarter 2024 Earnings: In Line With Expectations
|
|
May 10
|
Cytosorbents Corporation (NASDAQ:CTSO) Q1 2024 Earnings Call Transcript
|
|
May 9
|
CytoSorbents Reports First Quarter 2024 Results
|
|
May 2
|
CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe
|
|
Apr 26
|
CytoSorbents to Report First Quarter 2024 Operating and Financial Results
|
|
Apr 17
|
STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
|
|
Apr 4
|
CTSO: CytoSorbents Expects Significant Gross Margin Expansion in 2024.
|
|
Mar 20
|
These Analysts Think Cytosorbents Corporation's (NASDAQ:CTSO) Sales Are Under Threat
|
|
Mar 16
|
Cytosorbents Full Year 2023 Earnings: Misses Expectations
|
|
Mar 15
|
Cytosorbents Corporation (NASDAQ:CTSO) Q4 2023 Earnings Call Transcript
|
|
Mar 15
|
Q4 2023 Cytosorbents Corp Earnings Call
|
|
Mar 14
|
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
|
|
Mar 6
|
CytoSorbents to Report Fiscal 2023 Operating and Financial Results
|
|
Dec 18
|
Insider Spends US$100k Buying More Shares In Cytosorbents
|
|
Dec 13
|
CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering
|
|
Sep 1
|
CytoSorbents Announces Resignation of Chief Financial Officer Alexander D’Amico
|
|
Aug 31
|
CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil
|
|
Apr 26
|
CytoSorbents to Report First Quarter 2023 Operating and Financial Results
|